Corvair vs Cleerly ISCHEMIA
AI Verdict
Choose Corvair if…
Choose Corvair if you need rapid, AI-assisted interpretation of standard 10-second resting diagnostic ECGs to quickly identify a wide range of cardiac rhythms and morphologies. This tool is ideal for healthcare professionals in emergency medicine, internal medicine, or general cardiology seeking to enhance their diagnostic confidence and streamline the initial assessment of cardiac conditions.
View Corvair →Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease, including the likelihood of vessel-level ischemia, based on CCTA scans. This AI-powered solution is best suited for cardiologists and radiologists who need detailed insights into coronary plaque characteristics, stenosis severity, and functional significance to guide personalized diagnosis and treatment planning.
View Cleerly ISCHEMIA →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Corvair | Cleerly ISCHEMIA |
|---|---|---|
| Deployment | Cloud, Mobile App | Web-based solution |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CorvairCorvair (Tool A) is designed as an API library that integrates into existing ECG devices and workflows, requiring only 4 ECG leads for analysis and providing automated interpretations reviewable by healthcare professionals. This approach offers a simpler and more streamlined integration into common clinical practice compared to Cleerly ISCHEMIA (Tool B), which involves more complex CCTA imaging, data transfer, and web-based platform review.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA (Tool B) provides a more profound and actionable clinical value by offering detailed, vessel-level ischemia likelihood, non-invasive fractional flow reserve (FFR) estimation, and comprehensive coronary plaque characterization from CCTA scans. These insights directly inform personalized diagnosis and treatment planning for coronary artery disease, a level of specific and functional detail that surpasses the broader ECG interpretation offered by Corvair (Tool A).
Pricing & Value
Cleerly ISCHEMIAWhile both tools require contacting the vendor for definitive pricing, Cleerly ISCHEMIA (Tool B) offers greater transparency by publicly indicating a retail price (even if discounted) and a specific CPT code (75580) for billing. This information aids providers in understanding potential reimbursement and the overall cost structure, whereas Corvair's (Tool A) pricing remains entirely opaque.
Enterprise Readiness
Cleerly ISCHEMIABoth tools demonstrate strong foundational enterprise readiness with FDA clearance, HIPAA compliance, and BAA availability. However, Cleerly ISCHEMIA (Tool B) has a distinct advantage with its explicit integration with PowerScribe via API, which is crucial for seamless integration into existing radiology reporting workflows within enterprise imaging environments.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA (Tool B) demonstrates higher innovation by leveraging AI to derive complex functional and anatomical insights from CCTA scans, such as non-invasive FFR estimation and detailed plaque characterization. This moves beyond enhanced interpretation of existing diagnostic data to offer a novel, comprehensive approach to understanding coronary artery disease and guiding treatment.
Support & Docs
TieBoth companies offer clear channels for support, including email and online contact forms. AliveCor (parent company of Corvair) provides general customer service with extended hours, including weekends, and offers FAQs and user manuals for its broader product line. Cleerly provides dedicated support during business hours and a comprehensive resource hub with publications and patient education. Without specific details on Corvair's developer-focused documentation or specialized support for its API, it is difficult to definitively declare a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Corvair | Cleerly ISCHEMIA |
|---|---|---|
| Name | Corvair | Cleerly ISCHEMIA |
| Company | AliveCor | Cleerly |
| Description | Corvair by AliveCor is an FDA-cleared AI ECG analysis system that assists healthcare professionals in interpreting resting diagnostic ECGs with 35 cardiac determinations. | Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. |
| Categories | Cardiology AI | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Radiology |
| Key Features | AI-powered ECG analysis system, Analyzes 10-second ECGs, Provides 35 cardiac determinations (14 rhythm, 21 morphology), Assists healthcare professionals in interpreting resting diagnostic ECGs, Compatible with standard diagnostic-bandwidth ECG recordings (wet Ag/AgCl electrodes), Requires only 4 ECG leads for analysis, Automated interpretation reviewable by HCP, ISO 42001 certified AI Management System | AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination, Coronary plaque characterization (volume, type, location), Stenosis severity assessment, 3D digital models of coronary arteries, Comprehensive interactive web-based reports, Integration with PowerScribe via API |
Videos
Demos, reviews, and walkthroughs featuring Corvair and Cleerly ISCHEMIA.
Frequently Asked Questions
More Comparisons
More matchups featuring Corvair or Cleerly ISCHEMIA
Backers
Who funded each tool's parent company.